Arch Biopartners

Arch Biopartners Inc. is a clinical-stage company focused on developing innovative technologies with the potential for significant medical or commercial impact. Arch is developing a range of new drug candidates that inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP-1) pathway for various medical indications.